SCHEMBL4648902

SCHEMBL4648902

O=C1CN(c2cc(CN(Cc3ccccc3)C(=O)OCc3ccccc3)ccc2OCc2ccccc2)S(=O)(=O)N1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 6/20 0.45
FFAR4 Q5NUL3 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35
RAB9A P51151 1/20 0.35
RAF1 P04049 1/20 0.35
MAP2K1 Q02750 1/20 0.35
SNRNP200 O75643 1/20 0.35
FOLH1 Q04609 1/20 0.34
PTGES O14684 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4646906 0.82 PTPN1 (0.53) PTPN1FFAR4SMN1; SMN2NPC1RAB9A
SCHEMBL4646708 0.78 PTPN1 (0.60) PTPN1FFAR4GAA
SCHEMBL4643306 0.78 PTPN1 (0.53) PTPN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL4643501 0.78 PTPN1 (0.62) PTPN1FFAR4SNRNP200
SCHEMBL4684096 0.77 FFAR4 (0.36) FFAR4MEN1KMT2ATRPM8GAA
SCHEMBL4958442 0.76 PTPN1 (0.42) PTPN1FFAR4RAF1MAP2K1
SCHEMBL4646595 0.76 PTPN1 (0.53) PTPN1FFAR4SNRNP200
SCHEMBL4647040 0.75 PTPN1 (0.50) PTPN1FFAR4SMN1; SMN2SNRNP200ALDH1A1
Potassium SCHEMBL4647048 0.75 PTPN1 (0.50) PTPN1FFAR4SMN1; SMN2SNRNP200ALDH1A1
SCHEMBL646919 0.74 PTPN1 (0.47) PTPN1NPC1RAB9ASNRNP200ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1960377-A1 l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS Novartis AG (CH) 2008-08-27 EP disclosed
WO-2007067614-A1 l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors PTPRS, IRS1, PTPMT1 PTPN1 10/4885FFAR4 1923/4885MEN1 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.